Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma

N6-methyladenosine (m6A) has been involved in diverse biological processes in cancer, but its function and clinical value in clear cell renal cell carcinoma (ccRCC) remain largely unknown. In this study, we found that 1453 m6A-modified differentially expressed genes (DEGs) of ccRCC were mainly enric...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhenyu Yang, Bo Peng, Yongbo Pan, Yinmin Gu
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	m6a co-expression network mettl14 biomarker clear cell renal cell carcinoma Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/8aa872fcdd8042279b26c4fa6a633749
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8aa872fcdd8042279b26c4fa6a633749
record_format	dspace
spelling	oai:doaj.org-article:8aa872fcdd8042279b26c4fa6a6337492021-11-04T15:51:54ZAnalysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma2165-59792165-598710.1080/21655979.2021.1995574https://doaj.org/article/8aa872fcdd8042279b26c4fa6a6337492021-10-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1995574https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987N6-methyladenosine (m6A) has been involved in diverse biological processes in cancer, but its function and clinical value in clear cell renal cell carcinoma (ccRCC) remain largely unknown. In this study, we found that 1453 m6A-modified differentially expressed genes (DEGs) of ccRCC were mainly enriched in cell cycle, PI3K-AKT, and p53 signaling pathways. Then we constructed a co-expression network of the 1453 m6A-modified DEGs and identified a most clinically relevant module, where NUF2, CDCA3, CKAP2L, KIF14, and ASPM were hub genes. NUF2, CDCA3, and KIF14 could combine with a major RNA m6A methyltransferase METTL14, serving as biomarkers for ccRCC. Real-time quantitative PCR assay confirmed that NUF2, CDCA3, and KIF14 were highly expressed in ccRCC cell lines and ccRCC tissues. Furthermore, these three genes were modified by m6A and negatively regulated by METTL14. This study revealed that NUF2, CDCA3, and KIF14 were m6A-modified biomarkers, representing a potential diagnostic, prognostic, and therapeutic target for ccRCC.Zhenyu YangBo PengYongbo PanYinmin GuTaylor & Francis Grouparticlem6aco-expression networkmettl14biomarkerclear cell renal cell carcinomaBiotechnologyTP248.13-248.65ENBioengineered, Vol 0, Iss 0 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	m6a co-expression network mettl14 biomarker clear cell renal cell carcinoma Biotechnology TP248.13-248.65
spellingShingle	m6a co-expression network mettl14 biomarker clear cell renal cell carcinoma Biotechnology TP248.13-248.65 Zhenyu Yang Bo Peng Yongbo Pan Yinmin Gu Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
description	N6-methyladenosine (m6A) has been involved in diverse biological processes in cancer, but its function and clinical value in clear cell renal cell carcinoma (ccRCC) remain largely unknown. In this study, we found that 1453 m6A-modified differentially expressed genes (DEGs) of ccRCC were mainly enriched in cell cycle, PI3K-AKT, and p53 signaling pathways. Then we constructed a co-expression network of the 1453 m6A-modified DEGs and identified a most clinically relevant module, where NUF2, CDCA3, CKAP2L, KIF14, and ASPM were hub genes. NUF2, CDCA3, and KIF14 could combine with a major RNA m6A methyltransferase METTL14, serving as biomarkers for ccRCC. Real-time quantitative PCR assay confirmed that NUF2, CDCA3, and KIF14 were highly expressed in ccRCC cell lines and ccRCC tissues. Furthermore, these three genes were modified by m6A and negatively regulated by METTL14. This study revealed that NUF2, CDCA3, and KIF14 were m6A-modified biomarkers, representing a potential diagnostic, prognostic, and therapeutic target for ccRCC.
format	article
author	Zhenyu Yang Bo Peng Yongbo Pan Yinmin Gu
author_facet	Zhenyu Yang Bo Peng Yongbo Pan Yinmin Gu
author_sort	Zhenyu Yang
title	Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
title_short	Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
title_full	Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
title_fullStr	Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
title_full_unstemmed	Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
title_sort	analysis and verification of n6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/8aa872fcdd8042279b26c4fa6a633749
work_keys_str_mv	AT zhenyuyang analysisandverificationofn6methyladenosinemodifiedgenesasnovelbiomarkersforclearcellrenalcellcarcinoma AT bopeng analysisandverificationofn6methyladenosinemodifiedgenesasnovelbiomarkersforclearcellrenalcellcarcinoma AT yongbopan analysisandverificationofn6methyladenosinemodifiedgenesasnovelbiomarkersforclearcellrenalcellcarcinoma AT yinmingu analysisandverificationofn6methyladenosinemodifiedgenesasnovelbiomarkersforclearcellrenalcellcarcinoma
_version_	1718444726124806144

Analysis and verification of N6-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma

Ejemplares similares